Anandron (RU 23908) associated to surgical castration in previously untreated stage D prostate cancer: a multicenter comparative study of two doses of the drug and of a placebo.
Brisset
J M
JM
Centre Médico-Chirurgical de la Porte de Choisy, Paris.
Boccon-Gibod
L
L
Botto
H
H
Camey
M
M
Cariou
G
G
Duclos
J M
JM
Duval
F
F
Gontiès
D
D
Jorest
R
R
Lamy
L
L
D000368:Aged; D000726:Androgen Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage* / Q000009:adverse effects; D048289:Imidazolidines; D008297:Male; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000401:mortality / Q000628:therapy*
D000726:Androgen Antagonists; D007093:Imidazoles; D048289:Imidazolidines; C021277:nilutamide